Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Increased to $11.00 by Analysts at Wedbush

Karyopharm Therapeutics (NASDAQ:KPTI) had its price objective lifted by Wedbush from $6.00 to $11.00 in a report published on Monday morning.

A number of other research analysts have also recently commented on the stock. BidaskClub upgraded shares of Zumiez from a sell rating to a hold rating in a research report on Saturday, June 22nd. Robert W. Baird reiterated an outperform rating and set a $25.00 price target (up from $15.00) on shares of Karyopharm Therapeutics in a research report on Friday, July 5th. ValuEngine upgraded shares of Vistra Energy from a hold rating to a buy rating in a research report on Wednesday, July 3rd. Finally, HC Wainwright reiterated a buy rating and set a $48.00 price target (down from $52.00) on shares of CELYAD SA/ADR in a research report on Friday, July 5th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $17.41.

NASDAQ KPTI traded down $0.18 on Monday, reaching $7.61. 1,699,790 shares of the company’s stock traded hands, compared to its average volume of 1,835,867. Karyopharm Therapeutics has a 12 month low of $3.92 and a 12 month high of $21.71. The company has a current ratio of 6.19, a quick ratio of 6.19 and a debt-to-equity ratio of 0.98. The stock has a 50-day moving average price of $6.28. The firm has a market cap of $463.18 million, a PE ratio of -2.42 and a beta of 2.44.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.25). Karyopharm Therapeutics had a negative net margin of 1,005.85% and a negative return on equity of 119.66%. The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.75 million. On average, equities analysts predict that Karyopharm Therapeutics will post -3.8 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the company. Two Sigma Investments LP grew its holdings in shares of Karyopharm Therapeutics by 53.2% in the fourth quarter. Two Sigma Investments LP now owns 611,153 shares of the company’s stock worth $5,727,000 after purchasing an additional 212,196 shares during the last quarter. FMR LLC grew its holdings in shares of Karyopharm Therapeutics by 51.5% in the fourth quarter. FMR LLC now owns 1,875,140 shares of the company’s stock worth $17,570,000 after purchasing an additional 637,357 shares during the last quarter. Capital Impact Advisors LLC grew its holdings in shares of Karyopharm Therapeutics by 50.4% in the fourth quarter. Capital Impact Advisors LLC now owns 153,449 shares of the company’s stock worth $1,401,000 after purchasing an additional 51,443 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Karyopharm Therapeutics by 79.1% in the fourth quarter. Deutsche Bank AG now owns 479,323 shares of the company’s stock worth $4,489,000 after purchasing an additional 211,764 shares during the last quarter. Finally, Premier Asset Management LLC bought a new position in shares of Karyopharm Therapeutics in the fourth quarter worth approximately $282,000. Hedge funds and other institutional investors own 84.20% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

Further Reading: Understanding Analyst Recommendations

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.